Io Therapeutics, Inc., Presented Data from Studies of IRX4204, the Company’s Phase II Clinical Development Stage, Highly Selective Third Generation RXR Nuclear Receptor Agonist Compound, Supporting Its Potential Use for Prevention and Treatment of Normal Aging-related Neurodegeneration, Parkinson’s Disease, and Alzheimer’s Disease

SPRING, Texas, Jul. 9 (Korea Bizwire) — Io Therapeutics, Inc., presented today results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease (PD), and Alzheimer’s disease (AD), with its clinical stage experimental therapeutic RXR nuclear receptor agonist compound IRX4204. IRX4204 is a highly potent and highly selective, orally [...]